pharma-congress-molecular-medicine-2018-tracks

4 / 10

Page 19
Note:
O c t o b e r 1 9 - 2 0 , 2 0 1 8 | T o k y o , J a p a n
Pharma Congress 2018 & Molecular Medicine 2018
& Psychiatric Disorders 2018 Asian Journal of Biomedical and Pharmaceutical Sciences | ISSN: 2249-622X| Volume 8
International Conference on
PHARMACEUTICS AND NOVEL DRUG DELIVERY SYSTEMS
19th International Conference on
CELLULAR AND MOLECULAR MEDICINE
19th Annual Congress on
PSYCHIATRY AND PSYCHIATRIC DISORDERS
&
&
OF EXCELLENCE
IN INTERNATIONAL
MEETINGS
YEARS
Michael Hennig, Asian J Biomed Pharmaceut Sci 2018, Volume 8 | DOI: 10.4066/2249-622X-C3-008
X-RAY FREE ELECTRON LASER:
OPPORTUNITIES FOR DRUG DISCOVERY
Michael Hennig
LeadXpro AG Park InnovAARE, Switzerland
Past decades have shown the impact of structural information derived from
complexes of drug candidates with their protein targets to facilitate the
discovery of safe and effective medicines. Despite recent developments in
single particle cryo-electron microscopy, x-ray crystallography has been the
main method to derive high resolution structural information for drug design.
Recently, x-ray free electron laser (XFEL) have become available in the US
(LCLS), in Japan (SACLA) and in Europe (EUXFEL and SwissFEL). The unique
properties of x-ray free electron laser (XFEL) with unmet peak brilliance and
beam focus allow x-ray diffraction data recording and successful structure
determination from smaller and weaker diffracting crystals. This shortens
timelines in crystal optimization. To best capitalize on the XFEL advantage,
innovations in crystal sample delivery for the x-ray experiment, data collec-
tion and processing methods are required. This leads to the development of
serial crystallography which allows structure determination at more physio-
logically relevant room temperature. The ability of time resolution provided by
the femtosecond x-ray pulse, enables monitoring and capturing of dynamic
processes of ligand binding and associated conformational changes with
great impact to the design of candidate drug compounds. In addition, struc-
ture determination at room temperature gives more realistic data on protein
flexibility at the ligand binding site with new insights for computational chem-
istry. The talk will show the progress made in this area as well as examples for
successful application of serial crystallography.
Michael Hennig is a drug discovery research manager
with 22 years of experience in pharmaceutical industry.
He co-founded and is CEO and Chairman of the board of
leadXpro, an emerging biotech company and spin-out of
the Paul Scherrer Institute (ETH, Switzerland) that is ded-
icated to structure based drug discovery of membrane
protein targets. Formerly he worked 20 years at Roche re-
search Basel, Global Head and Principle Leader of discov-
ery technologies with responsibility for structure based
drug discovery, protein science, assay development and
HTS, corporate compound library, stem cell platform. In
addition, he is guest Professor at the University of Basel
in structural biology, gives lecture series in pharmacy, is
author of >75 paper and lecturer at conferences, inventor
of 8 patents in areas of technology, discovery and formu-
lation of drug substances.
BIOGRAPHY